Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders  Lauri M. Burroughs, Akiko.

Slides:



Advertisements
Similar presentations
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.
Advertisements

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission 
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Sabina Kersting, Leo F. Verdonck 
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia  Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.
Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial  Lauri M. Burroughs, Eneida.
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission  Jennifer L. Holter.
Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.
Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.
Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.
Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia  Daniella.
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
B Cells and Transplantation: An Educational Resource
Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative.
Biology of Blood and Marrow Transplantation
Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial 
Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic.
The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS- Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Treosulfan Based Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation for Treatment of Patients with Non-Malignant Diseases: Preliminary.
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS  Aaron T. Gerds, Ted A. Gooley,
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka.
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen  H.
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents  Moreno Festuccia, Kelsey Baker, Theodore.
A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.
Blood and Marrow Transplant Handbook
Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease  Haydar Frangoul, Li.
Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.
Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation  J.R. Molina,
Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Frédéric Baron, Effie W. Petersdorf, Ted Gooley, Brenda M
Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.
Transplantation of Unrelated Donor Umbilical Cord Blood for Nonmalignant Diseases: a Single Institution's Experience with 45 Patients  Tang-Her Jaing,
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H
Presentation transcript:

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders  Lauri M. Burroughs, Akiko Shimamura, Julie-An Talano, Jennifer A. Domm, Kelsey K. Baker, Colleen Delaney, Haydar Frangoul, David A. Margolis, K. Scott Baker, Eneida R. Nemecek, Amy E. Geddis, Brenda M. Sandmaier, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey  Biology of Blood and Marrow Transplantation  Volume 23, Issue 10, Pages 1669-1677 (October 2017) DOI: 10.1016/j.bbmt.2017.06.002 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 CD3+ and CD33+ donor chimerism in 14 patients conditioned with treosulfan-based conditioning. Shown are the percent donor chimerism of sorted peripheral blood CD3+ (A) and CD33+ (B) subsets according to day after transplant. Overlapping points at days +28, +80, +180, years, and at 100% chimerism, are jittered slightly to improve visibility. Biology of Blood and Marrow Transplantation 2017 23, 1669-1677DOI: (10.1016/j.bbmt.2017.06.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Disease-free survival. Shown is the Kaplan-Meier estimate of disease-free survival for 14 patients with bone marrow failure disorders who received treosulfan-based conditioning. Biology of Blood and Marrow Transplantation 2017 23, 1669-1677DOI: (10.1016/j.bbmt.2017.06.002) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.